A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a phase Ib study with cerdulatinib gel in mild to moderate atopic dermatitis, the compound significantly reduced epidermal thickness, decreased inflammatory dendritic cells and strongly impacted the inflammatory signature in transcriptomic analysis.
“In a phase Ib study with cerdulatinib gel in mild to moderate AD, the compound significantly reduced epidermal thickness, decreased inflammatory DCs and strongly impacted on the inflammatory signature in the transcriptomic analysis232.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [232]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221 · see citing works
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657 · see citing works
Self-citationThe immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman‐Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 651 · see citing works
Self-citationNew treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines
Renert‐Yuval, Y., & Guttman‐Yassky, E. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.10.005 · Cited by 126 · see citing works
Self-citationCoffey, G., Betz, A., DeGuzman, F. R., Pak, Y., Inagaki, M., Baker, D. C., Hollenbach, S. J., Pandey, A., & Sinha, U. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218164 · Cited by 93 · see citing works
Yasukawa, S., Miyazaki, Y., Yoshii, C., Nakaya, M., Ozaki, N., Toda, S., Kuroda, E., Ishibashi, K.-I., Yasuda, T., Natsuaki, Y., et al. (2014) · Nature Communications · doi:10.1038/ncomms4755 · Cited by 77 · see citing works
1083 Effect of RVT-502 therapy in the NC/Nga mouse model of atopic dermatitis
McHale, K. A., Harrington, W., Roeloffs, R., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.03.1096 · Cited by 3 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- in models of autoimmunity and B-cell cancer. J Pharmacol Exp Ther 2014;351:538e48.
Cited by
Sorted by citations
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623 · see citing works
Abdel-Mageed, H. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01642-z · Cited by 45 · see citing works
- Authors
- Piscitelli, S. C., Pavel, A. B., McHale, K., Jett, J. E., Collins, J., Gillmor, D., Tabolt, G., Li, R., Song, T., Zhang, N., Tallman, A. M., & Guttman-Yassky, E.
- Affiliations
- University of Mississippi (US)
- Icahn School of Medicine at Mount Sinai (US)
- ORCID
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 141
- Issue
- 7
- Pages
- 1847-1851
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W3121662252
- Cited by
- 30
- References
- 7
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 4
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Investigative Dermatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Keywords
- atopic dermatitis, topical gel, kinase inhibitors, epidermal hyperplasia, hyperkeratosis, inflammatory cell infiltration, target engagement, drug safety, mild-to-moderate atopic dermatitis
- MeSH terms
- Administration, Cutaneous, Adult, Dermatitis, Atopic, Double-Blind Method, Humans, Male, Pyrimidines, Severity of Illness Index, Sulfones, Drugs, Investigational, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
